Avantor, Inc. - AVTR STOCK NEWS

Avantor, Inc. (NYSE: AVTR) reported robust financial performance for Q3 2021, with net sales reaching $1.83 billion, a 14.3% increase year-over-year. The company achieved double-digit revenue growth and significant margin expansion, resulting in a net income of $156.8 million, a turnaround from a loss of $42.2 million in Q3 2020. Adjusted EBITDA rose 25.8% to $359.2 million. The company is poised for further growth, highlighted by the pending Masterflex acquisition and improved guidance for full-year results.

Avantor, Inc. (NYSE: AVTR) has opened a new single-use facility in Hillegom, Netherlands, in early October 2021. This facility, the company's second in Europe, enhances its cleanroom capacity and aims to support the growing demand for bioproduction. Located strategically between Amsterdam and Leiden, it will manufacture and deliver single-use solutions for all stages of biologics manufacturing.

Avantor's global footprint also includes facilities in the U.S. and China, and it has plans to acquire Masterflex®, further strengthening its offerings in bioproduction.

Avantor, a leading global provider of mission-critical products, has declared a quarterly cash dividend of $0.78 per share on its 6.250% Series A Mandatory Convertible Preferred Stock, effective November 15, 2021. The dividend represents a 1.560% yield and is payable to shareholders on record as of November 1, 2021. This initiative underscores Avantor's commitment to returning value to shareholders amidst its operational developments in the life sciences and advanced technologies sectors.

Avantor (NYSE: AVTR) announced the pricing of an $800 million private offering of 3.875% Senior Notes due November 1, 2029. The offering is expected to close on October 26, 2021, and the funds will be used to finance the acquisition of the Masterflex bioprocessing business from Antylia Scientific, along with associated fees. The Notes are being offered to qualified institutional buyers in a private transaction under exemption provisions of the Securities Act. This press release contains forward-looking statements subject to risks and uncertainties.

Avantor (NYSE: AVTR) has announced a private offering of senior notes by its subsidiary, Avantor Funding, Inc., to finance the acquisition of Masterflex bioprocessing and related assets from Antylia Scientific. The offering will be limited to qualified institutional buyers and will utilize proceeds from the notes, along with other financing sources. This strategic move aims to enhance Avantor's capabilities in the life sciences sector. The notes will not be registered under the Securities Act, emphasizing their private nature.

Avantor, Inc. (NYSE: AVTR) reported preliminary unaudited revenues for Q3 2021, totaling $1.83 billion, a significant increase of 14.3% year-over-year, with organic growth at 10.2%. The company anticipates finalizing its Masterflex debt financing in Q4 2021. These preliminary results, reflecting management's current views, are subject to change prior to the official earnings release on October 29, 2021. The unaudited figures have not been reviewed by independent auditors and should not replace full financial statements.

Avantor, Inc. (NYSE: AVTR) will release its third quarter 2021 financial results on October 28, 2021, after market close. A conference call to discuss the results is scheduled for October 29, 2021, at 7:30 a.m. EDT. Interested parties can join by phone or listen to a live webcast via the investors section of our website. The earnings press release will be available on the company’s website.

Avantor announced the pricing of an underwritten offering of 20,833,334 shares of its common stock at $42.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 2,976,190 shares. Proceeds will primarily finance the acquisition of Masterflex from Antylia Scientific and may also support general corporate purposes. The offering is set to close on September 16, 2021, pending customary conditions. Goldman Sachs, Citigroup, and BofA Securities are among the joint book-running managers for this transaction.

Avantor announced plans to offer $750 million of common stock in an underwritten offering, related to a pending acquisition of the Masterflex bioprocessing business. The proceeds will also support debt financing. Underwriters may purchase additional shares within 30 days. The company aims to use net proceeds primarily for the acquisition, or for general corporate purposes if not completed. The offering's managers include Goldman Sachs, Citigroup, and BofA Securities.